Serial entrepreneur Gary Glick sells another one of his startups for $229M — this time to an unlikely buyer
Gary Glick has proven himself, time and again, a nifty startup artist. After selling Lycera to Celgene, he held a streak for IFM Therapeutics — carving a plate of inflammation programs each time and turning the resulting subsidiary over to Big Pharma, while keeping the core discovery unit — and more recently lined up $270 million for precision oncology work at Scorpion.
His latest deal, though, looks a bit different.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.